Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical development partner Axis-Shield Diagnostics launches CE-marked ELISA assay for measurement of HBP

Regulatory information

The Hansa Medical development partner Axis-Shield Diagnostics has launched a CE-marked ELISA assay for measurement of Heparin Binding Protein, HBP. For more information on the assay, please visit www.heparinbindingprotein.com.

HBP is a new marker that has been shown to be useful in identifying patients on admission to the Emergency Department who are at risk of developing severe sepsis. Sepsis is the body's systemic inflammatory response to infection and can progress to severe sepsis, septic shock and ultimately multiple organ failure. Early diagnosis and appropriate treatment of severe sepsis is vital to improve the patient's chance of survival.

In 2009, Hansa Medical entered a collaboration and license agreement with Axis-Shield Diagnostics to further develop the Hansa Medical prototype HBP-assay (HMD-301) and subsequently launch a commercial assay.